• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Sarah Feldman, MD, MPH


  • Feldman S.Can the New Cervical Cancer Screening and Management Guidelines Be Simplified?.JAMA Intern Med. 2014 May 5.
  • Kim SC, Glynn RJ, Giovannucci E, Hernández-Díaz S, Liu J, Feldman S, Karlson EW, Schneeweiss S, Solomon DH.Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study.Ann Rheum Dis. 2014 Mar 11.
  • Earley A, Lamont JL, Dahabreh IJ, Cowan J, Feldman S, Uhlig K.Fluorescence In Situ Hybridization Testing for the Diagnosis of High-Grade Cervical Abnormalities: A Systematic Review.J Low Genit Tract Dis. 2014 Jan 28.
  • Kim SC, Gillet VG, Feldman S, Lii H, Toh S, Brown JS, Katz JN, Solomon DH, Schneeweiss S.Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer.Pharmacoepidemiol Drug Saf. 2013 Nov;22(11):1239-44.
  • Herfs M, Parra-Herran C, Howitt BE, Laury AR, Nucci MR, Feldman S, Jimenez CA, McKeon FD, Xian W, Crum CP.Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of low-grade squamous intraepithelial lesions.Am J Surg Pathol. 2013 Sep;37(9):1311-8.
  • Chadha M, Woode R, Sillanpaa J, Lucido D, Boolbol SK, Kirstein L, Osborne MP, Feldman S, Harrison LB.Early-stage breast cancer treated with 3-week accelerated whole-breast radiation therapy and concomitant boost.Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):40-4.
  • Charlton BM, Carwile JL, Michels KB, Feldman S.A Cervical Abnormality Risk Prediction Model: Can We Use Clinical Information to Predict Which Patients With ASCUS/LSIL Pap Tests Will Develop CIN 2/3 or AIS?.J Low Genit Tract Dis. 2013 Mar 12.
  • Esselen KM, Feldman S.Cost-effectiveness of cervical cancer prevention.Clin Obstet Gynecol. 2013 Mar;56(1):55-64.
  • Herfs M, Yamamoto Y, Laury A, Wang X, Nucci MR, McLaughlin-Drubin ME, Münger K, Feldman S, McKeon FD, Xian W, Crum CP.A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer.Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10516-21.
  • O'Neill JL, Feldman SR.Vitamine D analogue-based therapies for psoriasis.Drugs Today. 2010 May;46(5):351-60. Review.
  • Hanstede MM,Wise LA,Stewart EA,Feldman S.The relation of annual surgeon case volume to clinical outcomes and resource utilization in abdominal hysterectomy.J Reprod Med. 2009 Apr;54(4):193-202.
  • Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA.Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions.J Immunol. 2008 May 1;180(9):6116-31.
  • Chadha M, Feldman S, Boolbol S, Wang L, Harrison LB.The feasibility of a second lumpectomy and breast brachytherapy for localized cancer in a breast previously treated with lumpectomy and radiation therapy for breast cancer.Brachytherapy. 2008 Jan-Mar;7(1):22-8.
  • Cibas ES, Hong X, Crum CP, Feldman S.Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.Gynecol Oncol. 2007 Mar;104(3):702-6.
  • Feldman S, Goldstein DP, Berkowitz RS.Low-risk metastatic gestational trophoblastic tumors.Semin Oncol. 1995 Apr;22(2):166-71.
  • Feldman S, Cook EF, Harlow BL, Berkowitz RS.Predicting endometrial cancer among older women who present with abnormal vaginal bleeding.Gynecol Oncol. 1995 Mar;56(3):376-81.
  • Feldman S, Shapter A, Welch WR, Berkowitz RS.Two-year follow-up of 263 patients with post/perimenopausal vaginal bleeding and negative initial biopsy.Gynecol Oncol. 1994 Oct;55(1):56-9.
  • Feldman S, Berkowitz RS, Tosteson AN.Cost-effectiveness of strategies to evaluate postmenopausal bleeding.Obstet Gynecol. 1993 Jun;81(6):968-75.
  • Muntz HG, Bell DA, Lage JM, Goff BA, Feldman S, Rice LW.Adenocarcinoma in situ of the uterine cervix.Obstet Gynecol. 1992 Dec;80(6):935-9.